Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy

Life Sciences(2022)10.1016/j.lfs.2022.120463Source: DataRank Database

Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy is a research paper published in Life Sciences (2022). On theSindex it has a DataRank of 0. It has been cited 75 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

75 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 5.50)OA: closedTopics (43)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Hamidreza Saebfar,Mahmood Khaksary Mahabady ORCID,Sima Orouei,Kiavash Hushmandi ORCID,Maliheh Entezari ORCID

Live enrichment

PubMed:35259354 OpenAlex:https://openalex.org/W4221099978

Ministry of Education - Singapore

Grant: MOE-T2EP30120-0016

National Institutes of Health

Grant: R01AI050875

National Institutes of Health

Grant: R21AI121700

National Medical Research Council

National University of Singapore

FWCI

5.50

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S0024320522001631?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0024320522001631?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.lfs.2022.120463

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35259354

Fields of Study

RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryAdvanced biosensing and bioanalysis techniquesCell Line, TumorDoxorubicinDrug Delivery SystemsDrug Resistance, NeoplasmGenes, NeoplasmHumansNanoparticlesNeoplasmsRNA, Small Interfering

MeSH Terms

DoxorubicinHumansNeoplasmsDrug Delivery SystemsDrug Resistance, NeoplasmRNA, Small InterferingCell Line, TumorGenes, NeoplasmNanoparticles

Keywords

Small interfering RNAGene silencingNanocarriersDoxorubicinCancer cellRNA interferenceIntracellularCancer researchChemistryCell biologyBiologyCancerRNADrug deliveryGeneBiochemistryChemotherapyGene therapyDrug resistanceSiRNACancer ChemotherapySmart Nanoparticles

Sustainable Development Goals

SDG 0: Good health and well-being